2.1
Danicopan (Voydeya, Alexion) is indicated as 'an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia'.
2 Information about danicopan
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for danicopan.
Price
2.3
The list price of danicopan is £1,369.80 for a 90‑tablet bottle of 50‑mg tablets and £2,739.60 for a 90‑tablet bottle of 100‑mg tablets (company submission).
2.4
The company has a commercial arrangement. This makes danicopan available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.